tiprankstipranks
CRISM Therapeutics Earns MHRA Innovation Passport
Company Announcements

CRISM Therapeutics Earns MHRA Innovation Passport

Amur Minerals (GB:CRTX) has released an update.

Don't Miss Our Christmas Offers:

CRISM Therapeutics Corporation has been awarded an Innovation Passport for their ChemoSeed product for high grade gliomas by the UK’s MHRA, expediting the treatment’s development and access. Additionally, the company has received a £25,000 grant from SPARK The Midlands to further support their innovative cancer treatment technology. The CEO, Andrew Webb, highlighted these recognitions as significant milestones and endorsements for the potential of ChemoSeed to transform brain tumour treatments.

For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskCRISM Therapeutics Partners with Aixial Group for Phase 2 Glioblastoma Trial
TipRanks UK Auto-Generated NewsdeskCRISM Therapeutics Secures European Patent for Innovative Brain Tumor Treatment
TipRanks UK Auto-Generated NewsdeskCRISM Therapeutics Reports Positive Interim Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App